This article is more than 5 years old. Information may no longer be current.

AHA announces late-breaking clinical trials for scientific sessions

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The American Heart Association announced the lineup of late-breaking clinical trials scheduled for presentation at its Annual Scientific Sessions, to be held Nov. 12 to 16 in New Orleans.

The opening session will be moderated by Cardiology Today Chief Medical Editor Carl J. Pepine, MD, MACC, and will include the results of the EUCLID study, which focused on the effects of ticagrelor (Brilinta, AstraZeneca) compared with clopidogrel in patients with peripheral artery disease.

Carl J. Pepine

Other key late-breakers announced by the AHA include:

• The results for the Precision trial, which studied CV outcomes in patients taking celecoxib vs. ibuprofen or naproxen.

• A trial evaluating how cognition is affected by BP and cholesterol lowering.

• The FUTURE real-world study of fractional flow reserve-guided management vs. standard management in patients with atrial fibrillation requiring PCI.

• Results of a 5-year follow-up randomized comparison of single vs. bilateral internal mammary artery grafting and its effect on major CV outcomes.

• A placebo-controlled IVUS-guided trial on the effect of evolocumab (Repatha, Amgen) on progression of coronary atherosclerosis in patients treated with statins.

• The EFFECT-HF study of ferric carboxymaltose on exercise capacity in patients with chronic HF and iron deficiency.

• Primary results of the 6-month MOMENTUM 3 study, a multicenter study of MagLev Technology in patients undergoing mechanical circulatory support therapy with the HeartMate 3 device (Thoratec).

• The AHA also announced the presentations selected for the clinical science sessions. These include:

• Outcomes of the POSEIDON-DCM trial, a randomized comparison of allogeneic vs autologous mesenchymal stem cells in patients with nonischemic dilated cardiomyopathy.

• A multi-site investigation of real-world clinical implementation of CYP2C19 genotype-guided antiplatelet therapy after PCI.

• The NHLBI-funded CCTRN PACE study, evaluating the effects of administering aldehyde dehydrogenase bright cells to patients with intermittent claudication.

Cardiology Today and Cardiology Today’s Intervention will report live from the sessions. Visit Healio.com/Cardiology during the sessions for breaking news, videos, perspective from experts in the field on major results and announcements, and more.